Home › Trials › NCT06015477
Clinical trial No longer in our active list Interventional Ages 18 to 60

Using Ticagrelor instead of Dual Antiplatelet Therapy for treating unruptured intracranial aneurysms

Official title: Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study

Run by The First Affiliated Hospital with Nanjing Medical University · NCT06015477 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if using Ticagrelor alone instead of two blood-thinning medications can help adults with unruptured brain aneurysms have fewer bleeding problems after treatment.

More Intracranial Aneurysm trials

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment180 (estimated)
SponsorThe First Affiliated Hospital with Nanjing Medical University
Academic / other
Locations1 site (Nanjing, Jiangsu)
Trial IDNCT06015477 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-60 with unruptured intracranial aneurysms less than 10 mm who have undergone stent-assisted coiling without perioperative complications.

Probably not a fit

Patients with a history of chronic diseases or those requiring anticoagulation therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the effectiveness of Ticagrelor monotherapy compared to dual antiplatelet therapy in reducing bleeding complications for patients undergoing stent-assisted coiling for unruptured intracranial aneurysms. The study aims to determine if Ticagrelor, a P2Y12 inhibitor, can maintain ischemic protection while minimizing the risk of major bleeding. Participants will include adults aged 18-60 with specific eligibility criteria, and the trial will assess both safety and efficacy outcomes. The goal is to improve post-procedural management of patients with intracranial aneurysms.

Why it matters

Potential benefit: If successful, this approach could significantly reduce bleeding complications for patients undergoing treatment for unruptured intracranial aneurysms.

How similar studies have gone: Previous studies have indicated that P2Y12 inhibitor monotherapy may effectively reduce bleeding risks without increasing ischemic events, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patients with a definitive diagnosis of an unruptured intracranial aneurysm with imaging suggestive of an aneurysm \<10 mm
2. Patients who successfully underwent stent-assisted spring coil treatment for intracranial aneurysms without acute ischaemic or bleeding stroke events in the perioperative period
3. Age 18-60 years old
4. Patients with no previous history of chronic diseases such as hypertension, diabetes mellitus, coronary heart disease, hyperlipidaemia and so on
5. Agreed to participate in this study and gave informed consent for the collection and preservation of case data and the follow-up process.

Exclusion Criteria:

1. Planned surgery or intervention during the experiment requiring study drug discontinuation; (2) Contraindications requiring oral anticoagulation or aspirin or clopidogrel; (3) History of severe central nervous system damage (e.g., as a result of tumour, aneurysm, intracranial or spinal cord surgery); (4) Severe liver disease, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices), active hepatitis; (5 ) severe renal dysfunction (creatinine more than 1.5 times the upper limit of the normal range); (6) severe heart failure (NYHA class:III \~ IV); high risk for chronic arrhythmias (1st or 2nd degree atrioventricular block due to sinus node disease, bradycardic syncope without pacemaker); diagnosis or suspected diagnosis of acute coronary syndrome; bacterial endocarditis, pericarditis; (7) severe comorbidities or patients with active cancer with a life expectancy of less than 2 years; (8) participation in another clinical study using an experimental product within the past 30 days; currently receiving an experimental drug or device; and (9) pregnant, currently pregnant, or of childbearing potential without birth control or breastfeeding.

Where it's running

  • Hua Lu
    Nanjing, Jiangsu, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Intracranial Aneurysm 41Stent Complication 2The First Affiliated Hospital with Nanjing Medical University 147
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.